This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Law and Medicine  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Troyen A. Brennan, MD, MPH; Michelle M. Mello, M Phil, PhD, JD

JAMA. 2007;297:1255-1257.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Recent research would suggest that the US public should be pleased with the role the pharmaceutical industry plays in advancing public health. Somewhat surprisingly, given widespread concerns about the cost-inflating effects of drugs and other medical technologies, Cutler and colleagues have shown that spending on medical technology is generally cost-effective.^1-3 This is particularly true of new drugs, which often have contributed to stunning decreases in morbidity and mortality—for example, in cardiovascular disease.^4-5 It appears that the huge investments needed to bring new drugs and medical devices to market are wise.

So why is there so much dissatisfaction with the pharmaceutical industry today?⁶ The answer appears to lie in its reliance on a distinctive model of marketing. The mainstay of the marketing effort has been a combination of advertisements to physicians, direct visits to physicians by pharmaceutical sales representatives, . . . [Full Text of this Article]

Author Affiliations: Aetna Inc, Hartford, Conn (Dr Brennan); and Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass (Dr Mello).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Pharmaceutical Company Payments to Physicians: Early Experiences With Disclosure Laws in Vermont and Minnesota
Joseph S. Ross, Josh E. Lackner, Peter Lurie, Cary P. Gross, Sidney Wolfe, and Harlan M. Krumholz
JAMA. 2007;297(11):1216-1223.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Conflict of Interest in Reporting of Scientific Information
Irwin
Chest 2009;136:253-259.
ABSTRACT | FULL TEXT  

The Sound and the Fury: Financial Conflicts of Interest in Oncology
Djulbegovic et al.
JCO 2007;25:3567-3569.
FULL TEXT  

Sunshine Laws Shed Little Light
Journal Watch Cardiology 2007;2007:4-4.
FULL TEXT